Applied Therapeutics, Inc.
APLT
$0.3987
$0.00040.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 122.00K | 144.00K | 190.00K | -667.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 122.00K | 144.00K | 190.00K | -667.00K |
| Cost of Revenue | 11.70M | 14.83M | 10.00M | 12.22M | 15.30M |
| Gross Profit | -11.70M | -14.71M | -9.86M | -12.03M | -15.97M |
| SG&A Expenses | 21.33M | 15.04M | 10.58M | 9.07M | 5.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.02M | 29.87M | 20.58M | 21.28M | 20.34M |
| Operating Income | -33.02M | -29.74M | -20.44M | -21.09M | -21.01M |
| Income Before Tax | 44.01M | -68.59M | 2.90M | -83.94M | -37.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.01M | -68.59M | 2.90M | -83.94M | -37.68M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.01M | -68.59M | 2.90M | -83.94M | -37.68M |
| EBIT | -33.02M | -29.74M | -20.44M | -21.09M | -21.01M |
| EBITDA | -33.02M | -29.74M | -20.44M | -21.09M | -21.01M |
| EPS Basic | 0.30 | -0.48 | 0.02 | -0.67 | -0.34 |
| Normalized Basic EPS | 0.19 | -0.30 | 0.01 | -0.42 | -0.21 |
| EPS Diluted | 0.30 | -0.48 | -0.13 | -0.67 | -0.34 |
| Normalized Diluted EPS | 0.19 | -0.30 | 0.01 | -0.42 | -0.21 |
| Average Basic Shares Outstanding | 144.46M | 144.35M | 143.93M | 125.32M | 110.53M |
| Average Diluted Shares Outstanding | 144.46M | 144.35M | 152.39M | 125.32M | 110.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |